Challenges in current inhalable tobacco toxicity assessment models: A narrative review
- PMID: 38860150
- PMCID: PMC11163881
- DOI: 10.18332/tid/188197
Challenges in current inhalable tobacco toxicity assessment models: A narrative review
Abstract
Emerging tobacco products such as electronic nicotine delivery systems (ENDS) and heated tobacco products (HTPs) have a dynamic landscape and are becoming widely popular as they claim to offer a low-risk alternative to conventional smoking. Most pre-clinical laboratories currently exploit in vitro, ex vivo, and in vivo experimental models to assess toxicological outcomes as well as to develop risk-estimation models. While most laboratories have produced a wide range of cell culture and mouse model data utilizing current smoke/aerosol generators and standardized puffing profiles, much variation still exists between research studies, hindering the generation of usable data appropriate for the standardization of these tobacco products. In this review, we discuss current state-of-the-art in vitro and in vivo models and their challenges, as well as insights into risk estimation of novel products and recommendations for toxicological parameters for reporting, allowing comparability of the research studies between laboratories, resulting in usable data for regulation of these products before approval by regulatory authorities.
Keywords: electronic cigarettes; heated tobacco products; in vitro and in vivo; inhalation toxicology; vaping.
© 2024 Muthumalage T. et al.
Conflict of interest statement
The authors have each completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. T. Muthumalage reports that since the initial planning of the work, this study was supported by NIH (K99ES033835 and R00ES033835). A. Noel reports that since the initial planning of the work, this study was supported by NIH (NHLBI K01HL149053). Y. Thanavala reports that since the initial planning of the work, the Institute was supported from NIH (RO1HL142511) and NCI (P30CA016056), whilst in the past 36 months received payment or honoraria from NIH as a study section reviewer and reimbursement from grant for conference participation. A. Alcheva reports that since the initial planning of the work, payments were made to institution to support graduate studies, from NCI R01-CA179246 and Cancer Prevention Fund, Masonic Cancer Center. I. Rahman reports that since the initial planning of the work and in the past 36 months, this study was supported from NIH U54 (acknowledged).